These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38883641)

  • 21. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
    Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
    Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systematic review of characteristics, incidence, risk factors, and management.
    Kim S; Lim JU
    J Thorac Dis; 2022 May; 14(5):1684-1695. PubMed ID: 35693611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Disease-Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis.
    Chung JH; Cox CW; Montner SM; Adegunsoye A; Oldham JM; Husain AN; Vij R; Noth I; Lynch DA; Strek ME
    AJR Am J Roentgenol; 2018 Feb; 210(2):307-313. PubMed ID: 29140119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integration and Application of Radiologic Patterns From Clinical Practice Guidelines on Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis.
    Marinescu DC; Hague CJ; Muller NL; Murphy D; Churg A; Wright JL; Al-Arnawoot A; Bilawich AM; Bourgouin P; Cox G; Durand C; Elliot T; Ellis J; Fisher JH; Fladeland D; Grant-Orser A; Goobie GC; Guenther Z; Haider E; Hambly N; Huynh J; Johannson KA; Karjala G; Khalil N; Kolb M; Leipsic J; Lok S; MacIsaac S; McInnis M; Manganas H; Marcoux V; Mayo J; Morisset J; Scallan C; Sedlic T; Shapera S; Sun K; Tan V; Wong AW; Zheng B; Ryerson CJ
    Chest; 2023 Dec; 164(6):1466-1475. PubMed ID: 37541339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS/ERS/JRS/ALAT criteria.
    Yamakawa H; Sato S; Tsumiyama E; Nishizawa T; Kawabe R; Oba T; Kamikawa T; Horikoshi M; Akasaka K; Amano M; Kuwano K; Matsushima H
    J Thorac Dis; 2019 Dec; 11(12):5247-5257. PubMed ID: 32030242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.
    Flaherty KR; Wells AU; Cottin V; Devaraj A; Inoue Y; Richeldi L; Walsh SLF; Kolb M; Koschel D; Moua T; Stowasser S; Goeldner RG; Schlenker-Herceg R; Brown KK;
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34475231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
    Murata D; Azuma K; Matama G; Zaizen Y; Matsuo N; Murotani K; Tokito T; Hoshino T
    Thorac Cancer; 2023 Jan; 14(1):73-80. PubMed ID: 36377039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma LTBP2 as a potential biomarker in differential diagnosis of connective tissue disease-associated interstitial lung disease and idiopathic pulmonary fibrosis: a pilot study.
    Zou M; Hu X; Song W; Gao H; Wu C; Zheng W; Cheng Z
    Clin Exp Med; 2023 Dec; 23(8):4809-4816. PubMed ID: 37864077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrosing Progressive Interstitial Lung Disease in Rheumatoid Arthritis: A Multicentre Italian Study.
    Sebastiani M; Venerito V; Laurino E; Gentileschi S; Atzeni F; Canofari C; Andrisani D; Cassone G; Lavista M; D'Alessandro F; Vacchi C; Scardapane A; Frediani B; Cazzato M; Salvarani C; Iannone F; Manfredi A
    J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of High-Resolution CT Thorax in Diagnosing Interstitial Lung Disease and Its Association With Smoking and Connective Tissue Disorder.
    Doshi JA; Mundhra KS; Shah DS; Shah SN; Patel TV; Bhatt A
    Cureus; 2022 Nov; 14(11):e31107. PubMed ID: 36475156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
    Murata D; Azuma K; Murotani K; Matsuo N; Matama G; Tokito T; Sasada T; Hoshino T
    Lung Cancer; 2023 Oct; 184():107351. PubMed ID: 37639819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
    Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
    Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
    Zhang M; Fan Y; Nie L; Wang G; Sun K; Cheng Y
    Chest; 2022 Jun; 161(6):1675-1686. PubMed ID: 35026298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
    Horiuchi K; Ikemura S; Sato T; Shimozaki K; Okamori S; Yamada Y; Yokoyama Y; Hashimoto M; Jinzaki M; Hirai I; Funakoshi T; Mizuno R; Oya M; Hirata K; Hamamoto Y; Terai H; Yasuda H; Kawada I; Soejima K; Fukunaga K
    Oncologist; 2024 Jan; 29(1):e108-e117. PubMed ID: 37590388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deep Learning of Computed Tomography Virtual Wedge Resection for Prediction of Histologic Usual Interstitial Pneumonitis.
    Shaish H; Ahmed FS; Lederer D; D'Souza B; Armenta P; Salvatore M; Saqi A; Huang S; Jambawalikar S; Mutasa S
    Ann Am Thorac Soc; 2021 Jan; 18(1):51-59. PubMed ID: 32857594
    [No Abstract]   [Full Text] [Related]  

  • 37. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial.
    Inoue Y; Wells AU; Song JW; Xu Z; Kitamura H; Suda T; Okamoto M; Müller H; Coeck C; Rohr KB; Kolb M; Brown KK
    Respirology; 2023 May; 28(5):465-474. PubMed ID: 36642509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of nintedanib-induced gastrointestinal adverse events between patients with systemic sclerosis-associated interstitial lung disease and idiopathic interstitial pneumonias.
    Imai M; Okabayashi H; Akaike K; Hamada S; Masunaga A; Ichiyasu H; Sakagami T
    Respir Investig; 2024 May; 62(3):317-321. PubMed ID: 38395006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis.
    Yamaguchi T; Shimizu J; Hasegawa T; Horio Y; Inaba Y; Hanai N; Muro K; Hida T
    BMC Cancer; 2021 Aug; 21(1):924. PubMed ID: 34399710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
    Flaherty KR; Wells AU; Cottin V; Devaraj A; Walsh SLF; Inoue Y; Richeldi L; Kolb M; Tetzlaff K; Stowasser S; Coeck C; Clerisme-Beaty E; Rosenstock B; Quaresma M; Haeufel T; Goeldner RG; Schlenker-Herceg R; Brown KK;
    N Engl J Med; 2019 Oct; 381(18):1718-1727. PubMed ID: 31566307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.